The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).
 
Sumanta K. Pal
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
 
Javier Puente
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Pfizer; Roche
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Hilary Glen
Consulting or Advisory Role - Astellas Pharma; Eisai; Ipsen; Janssen; MSD
 
Piotr Koralewski
No Relationships to Disclose
 
Daniil Stroyakovskiy
No Relationships to Disclose
 
Boris Alekseev
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; ICON Clinical Research; Janssen; Merck; Pfizer; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Francis Parnis
No Relationships to Disclose
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Tudor Ciuleanu
Consulting or Advisory Role - A&D Pharma; Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
Travel, Accommodations, Expenses - A&D Pharma; Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Immunomedics; Myovant Sciences
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer
Consulting or Advisory Role - Alteogen; Bristol-Myers Squibb; GI Innovation; MSD; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Kaisa Sunela
Employment - Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Merck/Pfizer; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Ipsen
 
Karen O'Hara
Employment - Eisai
 
Terri A. Binder
Employment - Eisai
Stock and Other Ownership Interests - Amgen
 
Lixian Peng
Employment - Eisai
 
Alan D. Smith
Employment - Eisai
 
Sun Young Rha
Consulting or Advisory Role - Abbvie; Amgen; Daiichi Sankyo; Eisai; Ipsen; MSD Oncology; Novartis
Speakers' Bureau - Ipsen; Lilly
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Cellid; Eisai; Immunome; medpacto; MSD Oncology; Roche/Genentech; Sillajen